FDA Approves New Strength of Chemotherapy Drug Gleostine

NextSource Biotechnology LLC Jan. 20 said that the Food and Drug Administration has approved a five-milligram capsule of the chemotherapy agent Gleostine (lomustine).

Gleostine is approved for use as a single agent treatment or in combination with other approved chemotherapeutic agents, the company said. The product is indicated to treat brain tumors, as well as Hodgkin’s disease.

The product is now commercially available in the U.S, NextSource Biotechnology said.

“This approval adds a fourth dosage strength to the Gleostine product line-up that now includes 5, 10, 40, and 100 mg strengths, offering physicians a wider selection of dosage options to ...